Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Timing of Coupled Intravesical Gentamicin and Lactobacillus Rhamnosus LGG in SCI/D and NLUTD
NCT07643974Phase 1Not yet recruiting
- Sponsor
- MedStar Health Research Institute
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Lactobacillus rhamnosus GG in urinary tract infection (UTI) (2 arms), sponsored by MedStar Health Research Institute. Primary endpoint: Level of Lactobacillus rhamnosus GG in Urine at 24 hours. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Lactobacillus rhamnosus GG
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT07643974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643974.